BLTE
Belite Bio Inc

223
Loading...
Loading...
News
all
press releases
New Strong Sell Stocks for August 4th
BBCP, BLTE and CWH have been added to the Zacks Rank #5 (Strong Sell) List on August 4, 2025.
Zacks·1mo ago
News Placeholder
More News
News Placeholder
New Strong Sell Stocks for July 22nd
BLTE, DDD and ANNX have been added to the Zacks Rank #5 (Strong Sell) List on July 22, 2025.
Zacks·2mo ago
News Placeholder
Insights into Belite Bio's Upcoming Earnings
read more...
Benzinga·10mo ago
News Placeholder
Belite Bio, Inc.: Strong Buy Rating on Robust Financials and Promising Clinical Trials
Analyst Michael Okunewitch from Maxim Group maintained a Buy rating on Belite Bio, Inc. ADR (BLTE Research Report) and keeping the price target a...
TipRanks Financial Blog·1y ago
News Placeholder
Belite Bio Advances Novel Retinal Disease Treatment
Belite Bio, Inc. ADR (BLTE) has released an update. Belite Bio, Inc. has announced significant advancements in their second quarter with their nove...
TipRanks Financial Blog·1y ago
News Placeholder
Belite Bio (NASDAQ:BLTE) Shares Gap Down to $38.16
Shares of Belite Bio, Inc (NASDAQ:BLTE - Get Free Report) gapped down before the market opened on Wednesday . The stock had previously closed at $38.16, but opened at $35.29. Belite Bio shares last...
Zolmax·1y ago
News Placeholder
Belite Bio announces PMDA submission of Tinlarebant for trial in Japan
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·1y ago
News Placeholder
Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
Tinlarebant is Belite Bio's orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related...
Globe Newswire·1y ago
News Placeholder
Q1 2024 EPS Estimates for Belite Bio, Inc Raised by HC Wainwright (NASDAQ:BLTE)
Belite Bio, Inc (NASDAQ:BLTE Free Report) Analysts at HC Wainwright raised their Q1 2024 EPS estimates for Belite Bio in a research report issued to clients and investors on...
Zolmax·2y ago
News Placeholder
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...
Globe Newswire·2y ago

Latest BLTE News

View

Advertisement. Remove ads.

Advertisement. Remove ads.